Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Reata Pharmaceuticals advances SKYCLARYS, faces impurity challenges and growth opportunities

Reata Pharmaceuticals is making significant progress with FDA approvals and commercialization plans for SKYCLARYS. The company is strategically managing resources and focusing on key programs for long-term sustainability. Challenges with impurity issues and discontinuation of bardoxolone program are being addressed while opportunities for label expansion and new asset exploration are being pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Aphria

NVIDIA

Earnings results and favorable comments lifted several stocks.

Why Aphria, Reata Pharmaceuticals, and NVIDIA Jumped Today

Data from a phase 2 study looks promising.

Here's Why Reata Pharmaceuticals Skyrocketed Higher Today

Reata Pharmaceuticals Inc. (NASDAQ: RETA) shares jumped on Tuesday after the firm announced positive results from its midstage neuromuscular disorder drug trial.

Why This Neuromuscular Disorder Study Could Be the Next Big Thing

Reata Pharmaceuticals soared late Monday on positive results of a treatment for Friedreich's ataxia. The biotech recently reacquired omaveloxolone from AbbVie.

Biotech Stock Rockets 34% After Decision To Reacquire Its Drugs Pays Off

Reata Pharmaceuticals Inc. RETA, +4.99% shares were halted after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment.

Reata neuromuscular disorder drug meets study endpoint, stock halted

ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT

Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

IRVING, Texas, Oct.  11, 2019  (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl (bardoxolone) will be presented at the American Society of Nephrology Kidney Week 2019 Annual Meeting being held from November 5 – 10, at the Walter E. Washington Convention Center in Washington, D.C.

Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019

Reata Pharmaceuticals stock jumped Thursday after the biotech company reacquired the rights to several important drugs from pharmaceutical giant AbbVie.

Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs

Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock?

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q2 2019 Results - Earnings Call Transcript

Orphan (i.e., rare) disease used to be a barren investment field until Henri Termeer took activism to U.S. Congress. His work ultimately puts forward incentives for orphan drug innovators.

Reata: Blooming With Orphans

The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

Reata's (RETA) Kidney Candidate Gets Orphan Drug Status

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2019 Results - Earnings Call Transcript

Bihua Chen, founder and portfolio manager at Cormorant Asset Management, said on Monday she likes kidney disease drugmaker Reata Pharmaceutical.

Biotech developing kidney disease treatment jumps after hedge fund recommendation at conference

News for Reata Pharmaceuticals Stock (RETA)